amikacin sulfate / Generic mfg. - LARVOL DELTA

Prevalence and Antimicrobial Resistance Profiles of Bloodstream Pathogens in Feni, Bangladesh. (PubMed, Biomed Res Int) - "Gram-negative isolates exhibited high resistance to ampicillin, amoxyclav, and cefuroxime, whereas amikacin maintained > 70% sensitivity. Gram-positive isolates were largely resistant to third-generation cephalosporins but were very susceptible to gentamicin and ciprofloxacin...Amikacin demonstrated the highest efficacy, supporting its empirical consideration pending susceptibility results. These findings highlight the urgent need for local antibiogram development and strengthened regional resistance surveillance."

Journal • Infectious Disease

Antimicrobial resistance and real-time PCR detection of blaKPC in Klebsiella pneumoniae isolated from wound infections in a tertiary care hospital. (PubMed, Front Antibiot) - "Out of 560 K. pneumoniae isolates, 110 (19.6%) were resistant to meropenem. These resistant isolates also displayed high rates of multidrug resistance, with over 90% resistant to amikacin, ceftazidime, ampicillin, and cefazolin...In conclusion, K. pneumoniae isolates exhibit a concerning rate of carbapenem resistance mediated by the blaKPC gene. Antimicrobial stewardship and molecular surveillance are crucial for the prevention of the spread of carbapenem-resistant K. pneumoniae in clinical settings."

Journal • Infectious Disease • Pneumonia

Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared to Mueller-Hinton broth and artificial cerebrospinal fluid. (PubMed, Int J Antimicrob Agents) - "In CNS infections, when antimicrobial susceptibility testing in standard media does not result in adequate therapeutic options, we suggest to test the antimicrobial susceptibility of the causative bacterium in human CSF."

Journal • Infectious Disease

Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming. (PubMed, PLoS Pathog) - "Interestingly, the amino acid methionine significantly enhances the antibacterial activity of ERV against CR pathogens both in vitro and in vivo. Our findings underscore the potential of repurposing AMK in combination with ERV to combat CR pathogens and propose a novel strategy for controlling these infections through the combination of antibiotics with specific metabolites such as methionine."

Journal • Preclinical • Infectious Disease • Pneumonia

Rapid Adaptive Evolution under Combination Therapy in Klebsiella pneumoniae. (PubMed, ACS Infect Dis) - "Here, we investigated how resistance can emerge during exposure to combination therapy by conducting an in vitro evolutionary experiment with a clinical K. pneumoniae KPC-producing isolate (KP03, Brazil), which was initially susceptible to both amikacin and polymyxin B (AmkPol). Cross-resistance was also observed against colistin and certain antimicrobial peptides, raising concern for treatment options beyond the AmkPol combination. Although combination therapy represents an important treatment strategy, our findings demonstrate that K. penumoniae can rapidly evolve stable, high-level resistance under combination therapy, highlighting the need for a deeper understanding of how such regimens influence resistance development and the continued need to develop novel antibiotics strategies."

Journal • Infectious Disease • Pneumonia

Genomic Analysis of Coexisting β-Lactamase Plasmids in Klebsiella pneumoniae from an immunocompromised patient. (PubMed, J Glob Antimicrob Resist) - "Genomic profiling of KP-JZ177 reveals high-risk K. pneumoniae clone carrying extensive resistance and virulence determinants on multiple plasmids, including blaOXA-48 and blaNDM-1. Its plasmids similarity to geographically distant strains underscore global AMR circulation, emphasizing the need for enhanced surveillance of ST147 CRKP isolates in high-risk populations."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia

The Synergy between a Silver-Ruthenium Antimicrobial and aminoglycosides is based on severe macromolecular damage. (PubMed, bioRxiv) - "Combinational treatments significantly reduced the effective concentrations of gentamicin, tobramycin, kanamycin, and amikacin required for bacterial killing. Moreover, AGXX ® -aminoglycoside synergy was preserved in an artificial urine medium and across clinical UPEC isolates, underscoring its relevance to urinary tract infections. Together, these findings position AGXX ® as a potent aminoglycoside adjuvant that restores antibiotic efficacy through ROS-driven macromolecular damage, supporting its development for combination therapies against MDR bacterial infections."

Journal • Infectious Disease • Nephrology

Dual Mycobacterial Infection: Rare Coinfection of Mycobacterium tuberculosis and Nontuberculous Mycobacteria. (PubMed, Cureus) - "However, concurrent sputum cultures subsequently grew Mycobacterium abscessus and later Mycobacterium avium complex, prompting the addition of amikacin, cefoxitin, and azithromycin based on infectious disease consultation. This case illustrates the diagnostic and therapeutic challenges inherent to MTB-NTM coinfection, where distinguishing true NTM disease from colonization is critical, and underscores the importance of multidisciplinary management."

Journal • Gastrointestinal Disorder • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation. (PubMed, Clin Pharmacokinet) - "Nomogram-aided dosing interval adjustment of high-dose amikacin (30 mg/kg) maximized the efficacy and safety target attainment for critically ill patients with infections caused by susceptible K. pneumoniae."

Journal • PK/PD data • Infectious Disease • Pneumonia

Distribution and antibiotic resistance of Gram-negative bacteria from blood cultures before and during the COVID-19 pandemic. (PubMed, J Infect Dev Ctries) - "K. pneumoniae remained the most frequently isolated bacterium in both periods, while A. baumannii showed a significant increase during the pandemic. The 2.6-fold increase in A. baumannii may have been caused by the increased use of broad-spectrum antibiotics during the pandemic. These findings reflect data from a single hospital and should be validated by further multicenter studies."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Intensive care units-acquired urinary tract infections: a 5-year multicenter retrospective study in Istanbul. (PubMed, J Infect Dev Ctries) - "Universal recommendations on the use of catheters should be carefully applied to prevent the development of the infection. Patients who are infected by multidrug resistant (MDR) microorganisms should be followed carefully. Both centers should develop their own policies on this issue."

Journal • Retrospective data • Critical care • Infectious Disease • Nephrology • Pneumonia

Whole-genome and pangenome insights into Mycobacterium colombiense clinical isolates from human infections. (PubMed, PeerJ) - "Based on minimum inhibitory concentration values, moxifloxacin resistance was most prevalent (100%), followed by linezolid (90%), clarithromycin (30%), and amikacin (30%). This study provides valuable insight into the genomic diversity, antimicrobial resistance profiles, and virulence potential of M. colombiense isolates. These findings enhance understanding of the pathogen and may inform clinical management, targeted diagnostic development, and therapeutic strategies."

Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

The role of syndromic testing in pneumonia diagnosis: a comparison with culture methods. (PubMed, J Infect Dev Ctries) - "The pneumonia panel test provides higher positivity rates, faster results, and detects resistance genes, but lacks coverage for fungi and S. maltophilia."

Clinical • Journal • Retrospective data • Infectious Disease • Pneumonia • Respiratory Diseases

Amikacin Exposure and Its Association with Ototoxicity and Efficacy in Nontuberculous Mycobacterial Pulmonary Disease Treatment. (PubMed, Respir Med) - "Cumulative AMK exposure was associated with ototoxicity, and our findings allow prediction of ototoxicity onset using AMK TDM data."

Journal • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Combined bacteriophage and antibiotic therapy for refractory peritoneal dialysis-related peritonitis caused by Klebsiella pneumoniae. (PubMed, Nat Commun) - "Although this strain is found to be susceptible to amikacin and imipenem, a 14-day course of treatment with these antibiotics in the abdominal cavity fails to resolve the peritonitis...At the same time, oral fluconazole is given to prevent fungal infections...After this round of treatment, the patient remains healthy during the one-month follow-up. Our study suggests that personalized phage therapy combined with sensitive antibiotics can play a significant role in managing refractory peritonitis in patients undergoing peritoneal dialysis, showing promise for future applications."

Journal • Infectious Disease • Pneumonia • IL6

POTENTIAL FOR PHARMACOGENOMICS TO IMPROVE MEDICATION SAFETY AND EFFICACY IN AUSTRALIAN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS (EBMT 2026) - "Paired supportive care medications included allopurinol, sertraline, omeprazole, pantoprazole, voriconazole, ondansetron, tramadol, tacrolimus, flucloxacillin, carbamazepine and amikacin. We have demonstrated the prevalence of clinically relevant high-risk PGx phenotypes in a diverse paediatric oncology cohort. Many supportive care medications prescribed for paediatric HSCT patients are likely to be affected, with high prescribing rates observed for some medications with available PGx prescribing guidelines. These results highlight the potential for PGx guided prescribing to improve medication efficacy and reduce toxicity in a paediatric HSCT setting."

Biomarker • Clinical • Bone Marrow Transplantation • Transplantation • ABCG2 • CYP2C19 • CYP3A5 • HLA-B • NUDT15

MYCOBACTERIUM ABSCESSUS AS A COMPLICATION OF IMMUNOSUPPRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR CONGENITAL NEUTROPENIA (EBMT 2026) - "Despite treatment with systemic corticosteroids, ruxolitinib, ibrutinib, antiviral agents, and antifungal therapy for a probable invasive pulmonary aspergillosis infection, respiratory status continued to decline.By day +190, the patient presented with septic shock, for which invasive mechanical ventilation (IMV), fluid expansion and vasopressor therapy were required...BAL and blood cultures were positive for M. abscessus massiliense, confirming invasive pulmonary disease with bacteremia.Treatment consisted of intravenous amikacin, tigecycline, imipenem, and TDM guided azithromycin and clofazimine, in addition to ongoing antifungal therapy... This case illustrates how Mabs can emerge insidiously in pediatric alloSCT recipients, mimicking more common post-transplant complications and progressing rapidly to severe invasive infection. The patient's gradual recovery underscores the importance of early recognition, aggressive multidrug therapy, and careful reassessment of..."

Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Neutropenia • Nontuberculous Mycobacterial Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation • CSF3R

Nine-Year Trends in Antibiotic Resistance of Culture-Proven Pseudomonas aeruginosa Keratitis at a Tertiary Eye Center. (PubMed, Cornea) - "Over 9 years, Pseudomonas aeruginosa isolates retained sensitivity to older fluoroquinolones and aminoglycosides, while there was a trend toward increasing resistance to moxifloxacin. Cephalosporin and beta-lactam resistance remained high, except for ceftazidime and piperacillin-tazobactam. Despite the limitations of the study, these findings support a continued role for ciprofloxacin and aminoglycosides as empiric therapy options."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Pan-Resistant Pseudomonas aeruginosa Septic Shock in a Critically Ill Patient: A Case Report. (PubMed, Clin Med Insights Case Rep) - "Despite high-dose intravenous colistin, cefiderocol, and adjunctive amikacin, the infection persisted, leading to progressive multi-organ dysfunction...Meropenem (MIC 8 µg/mL; resistant) was trialed in combination with colistin for potential pharmacodynamic synergy...PDR Pseudomonas aeruginosa represents an urgent global threat. Until novel therapies become accessible, stringent stewardship, infection control, and preventive strategies remain the most effective defenses."

Journal • Chronic Kidney Disease • Critical care • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases • Septic Shock

Patient's features, clinical patterns and outcomes of non-tuberculous mycobacteria infections: A 10-year retrospective analysis from a third level university hospital. (PubMed, J Clin Tuberc Other Mycobact Dis) - "Attributable mortality was independently associated with older age, , previous tuberculosis, cancer, autoimmune disorders, and use of nebulized amikacin. NTM infections remain challenging to manage, particularly among patients with comorbidities and immunosuppression. Our findings highlight the need for individualized care strategies, multidisciplinary approach, improved diagnostics, and enhanced surveillance of NTM infections in Europe."

Journal • Retrospective data • Bronchiectasis • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Systemic Ebselen Treatment Prevents Amikacin Induced Ototoxicity and Nephrotoxicity in Mice (ARO 2026) - "Background : Aminoglycosides (AGs), such as tobramycin and amikacin, commonly used to treat recurrent pulmonary infections, are ototoxic and nephrotoxic. 28-days of amikacin increased the severity and duration of ototoxicity that was significantly reduced by ebselen. Amikacin-induced nephrotoxicity (increased Cr) was significantly reduced by ebselen. Interestingly, no hyperacusis was observed in any group and may be a consequence of greater PTS."

Preclinical • Infectious Disease • Nephrology • Otorhinolaryngology • Respiratory Diseases

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. (PubMed, Antimicrob Agents Chemother) - "Combination regimens with aminoglycosides (amikacin or plazomicin) occasionally demonstrated synergy using traditional definitions based on viable colony counting, but they were able to consistently reduce bacterial turbidity and the emergence of filamentous cells that were observed during exposure to ceftazidime/avibactam + aztreonam. Combinations between ceftazidime/avibactam, aztreonam, and an aminoglycoside are a potentially promising therapeutic strategy to combat the rising threat posed by MBL-producing K. pneumoniae."

Journal • Infectious Disease • Pneumonia

In vitro activity of mecillinam in combination with amikacin against carbapenemase-producing K. pneumoniae clinical isolates (ESCMID Global 2026) - No abstract available

Combination therapy • Preclinical • Infectious Disease • Pneumonia

Comparative evaluation of four antimicrobial susceptibility testing (AST) methods for amikacin among carbapenemase-producing K. pneumioniae clinical isolates (ESCMID Global 2026) - No abstract available

Clinical